AI Article Synopsis
- The study aimed to analyze the relationship between serum adiponectin levels and cardiovascular complications in Type 1 Diabetes (T1D) using data from the DCCT/EDIC study.
- High levels of adiponectin were linked to a reduced risk of peripheral artery disease and carotid atherosclerosis but were also associated with an increased risk of cardiovascular events, particularly when adjusted for heart structure changes.
- The findings suggest that while adiponectin may offer protective benefits against certain vascular issues in T1D, its association with cardiovascular events is complex and influenced by cardiac health.
Article Abstract
Aim: By analyzing data from DCCT/EDIC study, we investigated the associations of serum adiponectin concentrations with macrovascular complications and cardiovascular events in T1D.
Materials And Methods: Adiponectin concentrations were measured in EDIC year 8. The participants (n = 1040) were divided into four groups by quartiles of adiponectin concentrations. The association of macrovascular complications and cardiovascular events were analyzed by using multivariable regression and Cox proportional hazards models.
Results: High adiponectin concentrations were associated with decreased risk of peripheral artery disease represented by ankle brachial index (ORs (95% CI): 0.22 (0.07-0.72), 0.48 (0.18-1.25), and 0.38 (0.14-0.99) in fourth, third, and second quartiles compared with first quartile), with reduced carotid intima-media thickness, and with increased LVEDV index. Moreover, high adiponectin concentrations were also associated with increased risk of any cardiovascular events (HRs (95% CI): 2.59 (1.10-6.06), 2.03 (0.90-4.59), and 1.22 (0.52-2.85)) and major atherosclerotic cardiovascular events (HRs (95% CI): 11.37 (2.04-63.43), 5.68 (1.04-31.07), and 3.76 (0.65-21.77) in fourth, third, and second quartiles compared with first quartile), however, after adjustments with LVEDV index, these associations were diminished.
Conclusions: Adiponectin may protect carotid atherosclerosis and peripheral artery disease in T1D. It may be associated with increased cardiovascular events, depending on cardiac structural changes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diabres.2023.110700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aspirin Inhibits the In Vitro Adipogenic Differentiation of Human Adipose Tissue-Derived Stem Cells in a Dose-Dependent Manner.
Int J Mol Sci
January 2025
Division of Hand Surgery, Plastic Surgery and Aesthetic Surgery, University Hospital, LMU Munich, Ziemssenstraße 5, 80336 Munich, Germany.
Aspirin (ASA) is one of the most used medications worldwide and has shown various effects on cellular processes, including stem cell differentiation. However, the effect of ASA on adipogenesis of adipose tissue-derived stem cells (ASCs) remains largely unknown. Considering the potential application of ASCs in regenerative medicine and cell-based therapies, this study investigates the effects of ASA on adipogenic differentiation in human ASCs.
View Article and Find Full Text PDFStress and Strain: Differentiating the Responses to High and Moderate Heat Loads and Subsequent Recovery in Grain-Fed Feedlot Steers-Metabolic Hormones.
Animals (Basel)
January 2025
School of Agriculture and Food Sustainability, The University of Queensland, Gatton, QLD 4343, Australia.
The extent of endocrine changes in response to various levels of heat stress and subsequent recovery is not well understood. Two cohorts of 12 Black Angus steers were housed in climate-controlled rooms (CCR) and subjected to three thermal periods: PreChallenge (5 d), Challenge (7 d) and Recovery (5 d). PreChallenge and Recovery provided thermoneutral conditions.
View Article and Find Full Text PDFPlasma adiponectin and biomarker-confirmed Alzheimer's disease in a tertiary memory clinic.
J Neuroendocrinol
January 2025
Université Paris Cité, UMRS 1144, INSERM, Paris, France.
Alzheimer's disease (AD) is associated with early metabolic dysfunction and adiponectin, which may play a pathophysiological role. Adiponectin is implicated in the regulation of energy homeostasis, carbohydrate, and lipid metabolism, as well as in inflammation modulation. The aim of this study was to study whether plasma adiponectin levels were different between patients with AD confirmed by biomarkers and neurological control subjects.
View Article and Find Full Text PDFImpact of protein intake from a caloric-restricted diet on liver lipid metabolism in overweight and obese rats of different sexes.
Sci Rep
January 2025
Department of Cuisine and Nutrition, School of Tourism and Cuisine, Yangzhou University, Yangzhou, China.
In addition to being linked to an excess of lipid accumulation in the liver, being overweight or obese can also result in disorders of lipid metabolism. There is limited understanding regarding whether different levels of protein intake within an energy-restricted diet affect liver lipid metabolism in overweight and obese rats and whether these effects differ by gender, despite the fact that both high protein intake and calorie restriction can improve intrahepatic lipid. The purpose of this study is to explore the effects and mechanisms of different protein intakes within a calorie-restricted diet on liver lipid metabolism, and to investigate whether these effects exhibit gender differences.
View Article and Find Full Text PDFPan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
J Hepatol
January 2025
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida, United States of America. Electronic address:
Background & Aims: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with MASH. We tested its effect on insulin resistance at the level of different target tissues in relationship to change in intrahepatic triglyceride (IHTG) content.
Methods: This phase 2, single center, study randomized (1:1) 38 patients with T2D and MASLD to receive lanifibranor 800 mg or placebo for 24 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!